Trial · NCT06521255
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose limiting toxicity（DLT）and other adverse events (AEs) of tafasitamab and lenalidomide in combination with GemOx (TL-GemOx) assessed using CTCAE v5.0 | within 28 days after therapy initiation | |
| Primary | PFS assessed by IRC according to Lugano 2014 | 1-3 years approximately | |
| Secondary | Objective Response Rate (ORR) according to investigator. | 1-3 years approximately | |
| Secondary | Complete Response Rate (CRR) according to investigator. | 1-3 years approximately | |
| Secondary | Duration of Response (DOR) according to investigator. | 1-3 years approximately | |
| Secondary | Progression free survival (PFS) assessed by investigator according to the Lugano 2014 | 1-3 years approximately | |
| Secondary | Time to response (TTR) | 1-3 years approximately | |
| Secondary | Overall Survival (OS) | 1-3 years approximately | |
| Secondary | Time to next treatment (TTNT) | 1-3 years approximately | |
| Secondary | Adverse events assessed by CTCAE version 5.0 criteria. | 1-3 years approximately | |
| Secondary | Quality of life assessment: Patient-reported outcomes (PROs) on happiness and general health status based on Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) | 1-3 years approximately | |
| Secondary | Quality of life assessment: Patient-reported outcomes (PROs) on happiness and general health status based on EuroQol five dimensions questionnaire (EQ-5D-5L) | 1-3 years approximately |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06521255/registered